背景技术在我们先前的工作中,已经合成了几种哌嗪衍生的双(二烷基胺硫代羰基)二硫化物和二硫代氨基甲酸的二硫化物酯,并评估了它们的杀精和杀微生物功效。这些研究为开发处于临床前阶段的双重活性阴道杀菌剂提供了一些有希望的化合物。目的本研究的主要目的是对双(二烷基胺硫代羰基)二硫化物(4-15)和2,2'-二硫代二烷基双(3-(取代的-1-基)丙烷-2,1-二基)进行设计合成和生物学评估。作为非表面活性剂分子的二取代-1-碳二硫酸酯(19-28),能够消除阴道毛滴虫以及不可逆地快速固定100%人类精子。方法杀菌,抗毛滴虫,按照报道的方法进行了合成化合物的细胞毒性和生物相容性研究。结果发现双(二烷基胺硫代羰基)二硫化物(表1中的4-15)中,化合物4(MEC 0.02 mM)是最理想的杀精子活性,因为它的活性比Nonoxynol-9(N-9)高40倍,并且对阴道毛滴虫(MIC 0.02&1.10 mM
Substituted Dihydroimidazoles and their Use in the Treatment of Tumors
申请人:Chamoin Sylvie
公开号:US20100075966A1
公开(公告)日:2010-03-25
The invention relates to dihydroimidazoles of formula rac-(I),
wherein the radicals and symbols are as defined herein; their use as inhibitors of the interaction of the MDM2 protein with a p53-like peptide, new pharmaceutical formulations comprising said compounds, said compounds for use in the therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of proliferative diseases or for the manufacture of pharmaceutical formulations useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide, a pharmaceutical formulation e.g. useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide comprising said compound, methods of treatment comprising administration of said compounds to a warm-blooded animal, and/or processes for the manufacture of said compounds.
[EN] N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS<br/>[FR] N-4-(6-(HETERO)ARYLE-PYRIMIDINE-4-YLAMINOPHENYLE)-BEZENESULFONAMIDES EN TANT QU'INHIBITEURS DE KINASE
申请人:ALTANA PHARMA AG
公开号:WO2005070900A1
公开(公告)日:2005-08-04
Compounds of a certain formula 1 in which R1 and R2 have the meanings indicated in the description are novel kinase inhibitors. Formula (1), in which R1 is phenyl, phenyl substituted by R3 and/or R4, naphthalenyl, naphthalenyl substituted by R5 and/or R6, aryl1, aryl1 substituted by R7 and/or R8, R9, R10 or R11, R2 is phenyl, phenyl substituted by R12 and/or R13, naphthalenyl, naphthalenyl substituted by R14 and/or R15, aryl2, aryl2 substituted by R16 and/or R17 or a radical selected from Formula (2).
Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery
作者:Stephan G. Zech、Anna Kohlmann、Tianjun Zhou、Feng Li、Rachel M. Squillace、Lois E. Parillon、Matthew T. Greenfield、David P. Miller、Jiwei Qi、R. Mathew Thomas、Yihan Wang、Yongjin Xu、Juan J. Miret、William C. Shakespeare、Xiaotian Zhu、David C. Dalgarno
DOI:10.1021/acs.jmedchem.5b01552
日期:2016.1.28
activity of novel small molecule inhibitors of ChoKα. Starting from weakly binding fragments, we describe a structure based lead discovery approach, which resulted in novel highly potent inhibitors of ChoKα. In cancercell lines, our lead compounds exhibit a dose-dependent decrease of phosphocholine, inhibition of cell growth, and induction of apoptosis at low micromolar concentrations. The druglike lead
SUBSTITUTED INTERNAL VINYL-BORONIC ACIDS AND BORONIC ACID DERIVATIVES
申请人:Math Shivanand K.
公开号:US20120041193A1
公开(公告)日:2012-02-16
Disclosed herein are vinyl-bromides, vinyl-boronic acids and vinyl-boronic acid derivatives useful as synthetic intermediates for the preparation of therapeutic agents. Also disclosed are methods of synthesis of vinyl-bromides, vinyl-boronic acids and vinyl-boronic acid derivatives.
N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
申请人:Barsig Johannes
公开号:US20080242681A1
公开(公告)日:2008-10-02
Compounds of a certain formula 1 in which R1 and R2 have the meanings indicated in the description are novel kinase inhibitors. Formula (1), in which R1 is phenyl, phenyl substituted by R3 and/or R4, naphthalenyl, naphthalenyl substituted by and/or R6, aryl1, aryl1 substituted by R7 and/or R8, R9, R10 or R11, R2 is phenyl, phenyl substituted by R12 and/or R13, naphthalenyl, naphthalenyl substituted by R14 and/or R15, aryl2, aryl2 substituted by R16 and/or R17 or a radical selected from Formula (2).